51 results about "Antigen release" patented technology

The invention relates to a quantum dot immunochromatography detection card and a detection method for detecting ibuprofen through double-antibody sandwich competitive immunoassay. The detection card comprises a lining plate, a detection antigen release pad, a quantum dot probe release pad, a chromatography membrane and a water absorption pad. The detection antigen release pad comprises a detectionantigen formed by coupling ovalbumin and the ibuprofen; the quantum dot probe release pad comprises a quantum dot probe labelled with an anti-ovalbumin antibody; the chromatography membrane is provided with a detection line and a quality control line; the detection line fixes the anti-ibuprofen antibody; the quality control line fixes the ovalbumin antigen. The detection antigen is dissolved in adetection system from the release pad; the detection antigen, the detection antibody and a labelled antibody form a double-antibody sandwich immune complex for producing a fluorescence detection signal. Under the detection reference action of the quality control line, whether the ibuprofen is contained in a sample or not is judged according to the fluorescence signal on the detection line, so that the signal strength and the stability of detection are improved, and the detection sensitivity and the quantitative precision are improved.

The present invention relates to a Newcastle disease and avian flu antigen-antibody complex vaccine preparation method, which comprises: preparing avian flu inactivated antigen, preparing Newcastle disease inactivated antigen and avian flu inactivated yolk antibody, respectively emulsifying the inactivated Newcastle disease antigen, the inactivated avian flu antigen and the inactivated avian flu yolk antibody semi-finished product, and mixing. According to the present invention, the Newcastle disease and avian flu antigen-antibody complex vaccine with characteristics of vaccine immunization protection capability enhancing, antigen release delaying, good safety, high purity and production cost saving, suitable for all chicken flocks and especially providing safety and effectiveness for chicks and chicken having diseases is provided.

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents / compounds that cause antigen release and / or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

The invention provides intracellular pH-response polylactic-acid nanometer microspheres and a preparing method thereof. The intracellular pH-response polylactic-acid nanometer microspheres are prepared with the rapid membrane emulsification method in cooperation with the solvent evaporation / extraction method; as the proportion between water phase materials and oil phase materials in the nanometer microspheres is adjusted, the polylactic-acid nanometer microspheres prepared with the method are of thin-skin large-cavity structures and are even in particle diameter, and have the behavior of releasing embedded substances in a responding mode in the acid environment of intracellular endosome and lysosome. The intracellular pH-response polylactic-acid nanometer microspheres can controllably and rapidly release antigens in antigen presenting cells, antigen presenting cells and T cells can be more effectively activated, the problems that the antigen releasing speed of antigen-embedding polylactic-acid nanometer microspheres prepared with the traditional method is slow, and the particle diameter of the prepared nanometer microspheres is uneven are solved, the antigen loading capacity is high, preparing is easy, and the nanometer microspheres are hopefully developed into a novel vaccine delivery and adjuvant system.

The invention provides a method of making a vaccine for treating or preventing cancer in a patient or individual which comprises preparing the vaccine from cancer stem cells, from fractions, extracts, shed material or purified antigens derived from these cells, or from DNA or RNA coding for cancer stem cell associated antigens. In one embodiment of this invention, cancer stem cells are separated from unrelated cancer cell populations and then expended and cultured under conditions in which the cancer stem cells shed or release tumor antigens, and using the shed material or cancer stem cell antigens isolated from it as the vaccine. The invention further provides a vaccine and methods of treatment using the vaccine for any cancer is disclosed. Also disclosed are specific applications of this method to prepare such vaccines from antigens released or shed by cancer stem cells, and a particular application to make a shed, cancer stem cell, vaccine for breast cancer.

A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

The invention belongs to the technical field of medicines, and provides a chitosan-based antigen release rate-adjustable nano-vaccine, and a preparation method and an application thereof. Nano-particles are prepared by a rapid nano-complexation technology, and can efficiently co-encapsulate an antigen. The nano-vaccine uses a protein as the antigen; a ratio of chitosan to sodium triphosphate is changed at a specific pH value to obtain nano-vaccines having the same surface charge, nanometer particle size and drug loading amount, and the nano-vaccines have different antigen release rates; and the nano-vaccine with a fast antigen release rate promotes the presentation of the antigen in order to induce a strong immune response in the body and effectively inhibit tumor growth. The nano-vaccinehas the advantages of easiness in preparation, controllable components, and realization of large-batch continuous production.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention relates to a lateral antibody chip for detecting three mycotoxins by using a label-guided universal probe. The lateral antibody chip comprises a lining plate, and a difunctional antigenrelease pad, a universal fluorescent probe release pad, a chromatographic membrane and a water absorption pad which are sequentially adhered to the lining plate and are partially overlapped with one another, wherein the bifunctional antigen release pad comprises a specific marker coupled on the basis of a detection antigen formed by respectively coupling ovalbumin with AFB1, OTA and ZEN; the universal fluorescent probe release pad comprises a universal fluorescent probe labeled with an anti-specific marker antibody; the chromatographic membrane is provided with detection lines A, B and C and aquality control line, the detection lines A, B and C are respectively used for fixing an anti-AFB1 antibody, an anti-OTA antibody and an anti-ZEN antibody, and the quality control line is used for fixing the anti-specific marker antibody. According to the invention, the production of all detection reagents can be solved by using the universal fluorescent probe, the cost is reduced, and the quality control reliability is improved; and the signal intensity and the stability of detection are improved, and the detection sensitivity and the quantitative precision are improved.

The invention relates to a quantum-dot immunochromatography detection card and detection method for detecting tadalafil medicine with a ternary-system immune competition method. The detection card comprises a liner plate, a detection antigen releasing pad, a quantum-dot probe releasing pad, a chromatography film and a water absorption pad; the detection antigen releasing pad comprises a detectionantigen formed by coupling albumin eggs and the tadalafil medicine; the quantum-dot probe releasing pad comprises a quantum dot probe marked with an anti-albumin-egg antibody; the chromatography filmis provided with a detection line and a quality control line, the detection line fixes the antibody of the tadalafil medicine, and the quality control line fixes the albumin-egg antigen. The detectionantigen is dissolved into a detection system from the releasing pad, a ternary-system immune complex is formed by the detection antigen, the detection antibody and the marked antibody, and fluorescence detection signals are generated. Under the detection reference effect of the quality control line, whether the tadalafil medicine is contained in a sample or not is judged according to the fluorescence signals on the detection line, the signal strength and the stability of detection are improved, and the detection sensitivity and the quantitative accuracy are increased.

The invention relates to a quantum dot immunochromatography detection card of utilizing a ternary system immune competition method to detect sildenafil medicines and a detection method thereof. The detection card comprises a liner plate, a detection antigen release pad, a quantum dot probe release pad, a chromatography membrane, and a water absorption pad. The detection antigen release pad comprises a detection antigen, which is formed by coupling ovalbumin and sildenafil medicines. The quantum dot probe release pad comprises a quantum dot probe, which is labeled by an anti-ovalbumin antibody.The chromatography membrane is provided with a detection line and a quality control line. An anti-sildenafil antibody is fixed on the detection line. An ovalbumin antigen is fixed on the quality control line. The detection antigen is dissolved into a detection system from the release pad and forms a ternary system immune complex with the detection antibody and the labeled antibody, and a fluorescence detection signal is generated. Under the detection and reference effects of the quality control line, based on the fluorescence signal of the detection line, people can judge whether a sample contains sildenafil medicines or not, the strength and stability of detection signals are both enhanced, and the detection sensitivity and quantifying precision are improved.

The invention relates to a quantum dot immunochromatographic detection card and a quantum dot immunochromatographic detection method for detecting oxaprozin by using a double-antibody sandwich immunecompetition method. The detection card comprises a lining plate, a detection antigen release pad, a quantum dot probe release pad, a chromatographic membrane and an absorbent pad, wherein the detection antigen release pad contains a detection antigen formed by coupling ovalbumin and oxaprozin; the quantum dot probe release pad contains a quantum dot probe labeled with an anti-ovalbumin antibody; the chromatographic membrane is provided with a detection line and a quality control line, wherein the detection line immobilizes an oxaprozin antibody, and the quality control line immobilizes the ovalbumin antigen. The detection antigen is dissolved into a detection system from the release pad, and a double-antibody sandwich immune complex is formed by the detection antigen together with a detection antibody and a labeled antibody, so that a fluorescence detection signal is generated. Under the detection and reference function of the quality control line, whether a sample contains the oxaprozin or not can be judged according to the fluorescence signal on the detection line, so that the signal intensity and stability of the detection can be improved, and the detection sensitivity and the quantitative precision are enhanced.

The invention relates to an indomethacin quantum dot immunochromatographic detection card based on a signal amplification system and a detection method. The detection card comprises a liner plate, a detection antigen release pad, a quantum dot probe release pad, a chromatographic membrane and a water absorbent pad; the detection antigen release pad comprises a detection antigen coupled by ovalbumin and indomethacin; the quantum dot probe release pad comprises a quantum dot probe labeled with an anti-ovalbumin antibody; the chromatographic membrane is provided with a detection line and a quality control line, the detection line fixes an anti-indomethacin antibody, and the quality control line fixes an ovalbumin antigen. The detection antigen is dissolved from the release pad into a detection system to form a ternary system immune complex with a detection antibody and a labeled antibody so as to generate a fluorescence detection signal. Under the detection and reference functions of thequality control line, whether a sample contains the indomethacin is judged according to a fluorescence signal on the detection line, the signal intensity and stability of the detection can be increased, and the detection sensitivity and the quantitative precision are improved.

The invention provides a method for producing a composition for use as a vaccine for treatment or prevention of cancer, comprising collecting antigens released or shed by the type of tumor cell against which it is desired to prepare the vaccine; preparing mammalian dendritic cells in a culture from a mammalian blood, bone marrow or other tissue sample by culturing the blood, bone marrow, or other tissue sample under conditions that cause differentiation and proliferation of dendritic cells; separating dendritic cells from other cells in the culture; and exposing the dendritic cells to the shed antigens collected as described in paragraph a. above under conditions that result in the combination of the shed cancer antigens or their fragments and the dendritic cells. The invention also provides compositions for administration as a vaccine for the treatment of cancer, and other diseases.

The invention discloses a bispecific antibody fusion protein, a recombinant oncolytic virus and application of the bispecific antibody fusion protein and the recombinant oncolytic virus in preparation of drugs for treating tumors, the recombinant oncolytic virus can express and secrete a bispecific antibody HER2-BiTE, and the bispecific antibody HER2-BiTE can serve as an adapter to recruit T cell targeted HER2 positive tumor cells, so that the killing effect of the T cells on the tumor cells is improved; meanwhile, the oncolytic virus causes tumor cell lysis, tumor-associated antigen release and tumor microenvironment remodeling; the BiTE plays a role in tumor sites, so that the adverse reaction of systemic administration is relieved. The synergistic effect of the oncolytic virus and the bispecific antibody improves the tumor treatment effect.

This invention belongs to the field of biomedicine and specifically relates to an antigen-capturing and mannose receptor-targeting nanodrug, its preparation method, and its application. This nanodrug can capture tumor-associated antigens released after thermal ablation of cancer cells and, in combination with an FTO inhibitor, deliver them to tumor-infiltrating dendritic cells. After thermal ablation, the synergistic effect of the nanodrug and immune checkpoint blockade therapy inhibits distal tumor growth and improves long-term survival.

The application discloses a photosensitive carrier and a preparation method and application thereof, and belongs to the field of nanomaterials.The application relates to a glutathione-activated nano-immunopreparation compound with targeting property, and a structural general formula of the compound is shown as formula I.The photosensitive carrier is prepared by wrapping a TLR7 agonist in the nano-immunopreparation compound, so that the photosensitizer and the immunodrug activity are inhibited, the tumor-related antigens released after the photodynamic killing are combined with the activated immune checkpoint inhibitors to jointly induce a synergistic antitumor immune response, so that the growth of in-situ / distant tumors is inhibited and tumor metastasis is prevented; the activated photodynamic immunopreparation molecules not only realize synergistic treatment and obtain excellent tumor treatment efficiency, but also can avoid serious side effects in the tumor treatment process.

The invention relates to the technical field of medicine, in particular to an antigen double burst release self-boosting immune vaccine and application thereof.The antigen double burst release self-boosting immune vaccine is characterized in that antigens are loaded inside and outside complex coacervation microcapsules in the vaccine, nanoparticles are prepared through a nanoprecipitation method, the nanoparticles and cell membranes jointly entrap the antigens to form functional nanoparticles, and the functional nanoparticles are used as functional nanoparticles; the preparation method comprises the following steps: coating functionalized nanoparticles by using a micro-fluidic technology and a complex coagulation method to prepare microcapsules, coating the surface of the microcapsules by using dopamine hydrochloride auto-polymerization reaction to form coating microcapsules, and finally blending with the functionalized nanoparticles, thereby dividing the antigen into an inner part and an outer part. After entering a body, the nano-microparticle carrier double burst release vaccine is subjected to antigen double burst release with time lag intervals in different time periods; the prepared vaccine can release antigens firstly, then effectively collect and activate antigen presenting cells, the antigen presenting cells uptake the antigen presenting cells to cause immune response, and the generation of specific antibodies can be effectively induced by two times of antigen release through the time-delay coating, so that a traditional natural immune procedure is simulated.

The invention provides intracellular pH-response polylactic-acid nanometer microspheres and a preparing method thereof. The intracellular pH-response polylactic-acid nanometer microspheres are prepared with the rapid membrane emulsification method in cooperation with the solvent evaporation / extraction method; as the proportion between water phase materials and oil phase materials in the nanometer microspheres is adjusted, the polylactic-acid nanometer microspheres prepared with the method are of thin-skin large-cavity structures and are even in particle diameter, and have the behavior of releasing embedded substances in a responding mode in the acid environment of intracellular endosome and lysosome. The intracellular pH-response polylactic-acid nanometer microspheres can controllably and rapidly release antigens in antigen presenting cells, antigen presenting cells and T cells can be more effectively activated, the problems that the antigen releasing speed of antigen-embedding polylactic-acid nanometer microspheres prepared with the traditional method is slow, and the particle diameter of the prepared nanometer microspheres is uneven are solved, the antigen loading capacity is high, preparing is easy, and the nanometer microspheres are hopefully developed into a novel vaccine delivery and adjuvant system.

Methods of treating patients suffering from cancer using a combination of 1) an immunomodulatory agent; 2) a check point inhibitor; and 3) a cancer antigen releasing therapy are provided. In some aspects, the immunomodulatory agent is an anti-CD3 immunotoxin, the check point inhibitor inhibits the interaction of PD-1 and PD-L1 and the cancer antigen releasing therapy is radiation.

To provide a process where particle size and antigen encapsulation as well as antigen release can be precisely controlled.SOLUTION: The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making the TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).SELECTED DRAWING: Figure 1

The invention relates to a difunctional antigen guided sildenafil and tadalafil antibody array detection card. The detection card comprises a lining plate, and a difunctional antigen release pad, a universal fluorescent probe release pad, a chromatographic membrane and a water absorption pad which are sequentially adhered to the lining plate and are partially overlapped with one another, wherein the bifunctional antigen release pad comprises a specific marker coupled on the basis of a detection antigen formed by coupling ovalbumin with sildenafil and tadalafil respectively; the universal fluorescent probe release pad comprises a universal fluorescent probe labeled with an anti-specific marker antibody; the chromatographic membrane is provided with a detection line A, a detection line B anda quality control line which are respectively used for fixing an anti-sildenafil antibody, an anti-tadalafil antibody and the anti-specific marker antibody. According to the invention, the productionof all detection reagents can be solved by using the universal fluorescent probe, the cost is reduced, and the quality control reliability is improved; and the signal intensity and the stability of detection are improved, and the detection sensitivity and the quantitative precision are improved.

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents / compounds that cause antigen release and / or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

The invention relates to a SpaCBA-OVA liposome nanoparticle as well as a preparation method and application thereof. The SpaCBA-OVA liposome nanoparticle is formed by encapsulating SpaCBA and OVA in a liposome together, according to the SpaCBA-OVA lipidosome nanoparticles subjected to engineering modification, SpaCBA and OVA are jointly encapsulated in the lipidosome, so that continuous antigen release is given to encapsulated protein, and the limitation of mucosal vaccines is solved; through double receptor uptake, allergen presentation and immunomodulatory signal transduction are balanced, and the release of the dendritic cell immunomodulatory factor IL-10 / TGF-beta is enhanced, so that the problems proposed in the background technology can be well solved.

A method of inducing the sustained release of antibodies in milk comprising the step of: a) implanting at least one antigen releasing device adjacent to, within close proximity of or within at least one supramammary lymph node, wherein in use the antigen releasing device releases an antigen into the tissue area around the supramammary lymph node which stimulates antibody secretion into a mammary gland.

The invention discloses TIM-3 scFv bionic nanoparticles loaded with an A-D-A organic sound-sensitive agent and a preparation method and application of the TIM-3 scFv bionic nanoparticles loaded with the A-D-A organic sound-sensitive agent. The preparation method comprises the steps that a tetrahydrofuran solution of CH-H and a tetrahydrofuran solution of DSPE-PEG are added into deionized water, ultrasonic treatment is carried out, then rotary evaporation is carried out, concentration and drying are carried out, and the A-D-A organic sound-sensitive agent nanoparticles are obtained; the method comprises the following steps: obtaining a cell membrane of a macrophage with stable overexpression of an EGFP-TIM-3 scFv gene, then mixing the cell membrane with A-D-A organic sound-sensitive agent nanoparticles, and extruding through an extruder; the organic sound-sensitive agent can efficiently generate ROS and can directly kill tumor cells and induce ICD, meanwhile, TIM-3 scFv blocks TIM-3 signals on cDC1 cells, the antigen presentation function of the cDC1 cells is recovered, positive feedback circulation of sonodynamic killing, antigen release, cross presentation and T cell activation is formed, and the aim of treating colorectal cancer is achieved.

The invention relates to a lateral antibody chip for detecting diclofenac and indomethacin by using a marker antibody probe. The lateral antibody chip comprises a lining plate, and a difunctional antigen release pad, a universal fluorescent probe release pad, a chromatographic membrane and a water absorption pad which are sequentially adhered to the lining plate and are partially overlapped with one another, wherein the bifunctional antigen release pad comprises a specific marker coupled on the basis of a detection antigen formed by coupling ovalbumin with diclofenac and indomethacin respectively; the universal fluorescent probe release pad comprises a universal fluorescent probe labeled with an anti-specific marker antibody; the chromatographic membrane is provided with a detection line A, a detection line B and a quality control line which are respectively used for fixing an anti-diclofenac antibody, an anti-indomethacin antibody and the anti-specific marker antibody. According to the invention, the production of all detection reagents can be solved by using the universal fluorescent probe, the cost is reduced, and the quality control reliability is improved; and the signal intensity and the stability of detection are improved, and the detection sensitivity and the quantitative precision are improved.

Disclosed herein are immunotherapeutic constructs comprising a delivery particle, at least one adjuvant, and one or more therapeutic agents / compounds that cause antigen release and / or modulate immunosuppressive tumor microenvironment. These immunotherapeutic constructs create adaptive immunity or anti-cancer immune response(s) that can be used, for instance, to prevent and treat broad types of cancer. Further disclosed are uses of the immunotherapeutic constructs, including to prevent and treat cancer in humans and animals.

The invention relates to a quantum dot immunochromatographic detection card and a detection method for detecting oxaprozine by a double-antibody sandwich immunocompetitive method. The detection card includes a liner, a detection antigen release pad, a quantum dot probe release pad, a chromatographic membrane and a water-absorbent pad; the detection antigen release pad contains a detection antigen coupled by ovalbumin and oxaprozine; The dot probe release pad contains quantum dot probes marked with anti-ovalbumin antibody; the chromatographic membrane is provided with a detection line and a quality control line, the detection line is fixed with anti-oxaprozin antibody, and the quality control line is fixed with ovalbumin antigen. The detection antigen dissolves into the detection system from the release pad, forms a double-antibody sandwich immune complex with the detection antibody and the labeled antibody, and generates a fluorescent detection signal. Under the action of the detection reference of the quality control line, it is judged whether the sample contains oxaprozine according to the fluorescent signal on the detection line, which increases the signal strength and stability of the detection, and improves the detection sensitivity and quantitative precision.